Corient Private Wealth
RGNX icon

Corient Private Wealth’s Regenxbio RGNX Stock Holding History

Corient Private Wealth’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Buy
+217,661
New +$1.81M ﹤0.01% 1257

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Corient Private Wealth's RGNX Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Regenxbio (RGNX) in Q2 2026: 217,661 shares worth $2.61M. The stake represents ﹤0.01% of the portfolio and ranks #1257 among its holdings.

80 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Corient Private Wealth held 217,661 shares of Regenxbio worth $2.61M as of Q2 2026.
  • Regenxbio was a new Corient Private Wealth position in Q2 2026.
  • Regenxbio made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1257 holding.
  • 80 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.